Members  •  New members

Alexion, Astra Zeneca Rare Disease Joins FACCNE as New Elite Member

Proud to welcome Alexion, a pioneer in rare disease treatments, as a new FACCNE Elite Member.

We are delighted to welcome Alexion, AstraZeneca Rare Disease as a new FACCNE Elite Member.

Alexion is a global leader dedicated to transforming the lives of people living with rare diseases. For more than three decades, the company has pioneered breakthrough science and redefined what it means to live with a rare condition. Today, Alexion continues to advance a robust and diversified pipeline addressing areas of significant unmet medical need through a wide range of innovative modalities.

As part of AstraZeneca, Alexion is expanding its global presence to reach and serve more rare disease patients worldwide. With its headquarters in Boston, Massachusetts, and offices across the globe, the company remains at the forefront of rare disease innovation.

Rooted in its groundbreaking work translating the complex biology of the complement system into novel therapies, Alexion continues to push scientific boundaries and accelerate the development of life-changing medicines for patients and families who need them most.

For more information: https://alexion.us/about-us